Cargando…

Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World’s First Biosimilar Ranibizumab): A Comprehensive Review

Ranibizumab is approved for the treatment of several macular disorders, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO) and myopic choroidal neovascularization (mCNV), among others. The unaffordability of the innovator ranibizumab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Shashikant, Sharma, Tanishq, Prasad, Somdutt, Gopalakrishnan, Mahesh, Chaturvedi, Alok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216589/ https://www.ncbi.nlm.nih.gov/pubmed/34155608 http://dx.doi.org/10.1007/s40123-021-00362-1

Ejemplares similares

A Multicenter, Retrospective Study (RE-ENACT 2) on the Use of Razumab™ (World’s First Biosimilar Ranibizumab) in Wet Age-Related Macular Degeneration
por: Sharma, Shashikant, et al.
Publicado: (2019)

A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (World's First Biosimilar Ranibizumab) in Retinal Vein Occlusion
por: Sharma, Shashikant, et al.
Publicado: (2020)

Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study
por: Sharma, Shashikant, et al.
Publicado: (2021)

Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases
por: Chakraborty, Debdulal, et al.
Publicado: (2021)

Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab
por: Verma, Lalit, et al.
Publicado: (2021)

Subretinal Neovascular Membrane in Wet Age-Related Macular Degeneration Managed With Intravitreal Ranibizumab
por: Sharma, Tanishq S, et al.
Publicado: (2021)

Biomedical and Market Issues Surrounding the Advent of Biosimilars
por: Cline, Abigail, et al.
Publicado: (2016)

Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
por: Yanagi, Yasuo, et al.
Publicado: (2023)

Randomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration
por: Apsangikar, Prasad, et al.
Publicado: (2021)

Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
por: Yanagi, Yasuo, et al.
Publicado: (2023)

Comparison of Innovator vs. Biosimilar Ranibizumab in Treating Diabetic Macular Edema: A Multicenter Retrospective Study
por: Chakraborty, Debdulal, et al.
Publicado: (2022)

Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation
por: Ratra, Dhanashree, et al.
Publicado: (2021)

Efficacy of a biosimilar ranibizumab monotherapy for the treatment of retinopathy of prematurity
por: Prajapati, Vipul, et al.
Publicado: (2023)

Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial
por: Woo, Se Joon, et al.
Publicado: (2020)

Comparison of ranibizumab alone versus ranibizumab with targeted retinal laser for branch retinal vein occlusion with macular edema
por: Goel, Siddhi, et al.
Publicado: (2019)

Role of ranibizumab in management of macular degeneration
por: Singh, Rishi P, et al.
Publicado: (2007)

Advent of Elkosin
por: Banerji, Binoy
Publicado: (1950)

Evidence Integration in the Era of Information Flooding—The Advent of the Comprehensive Review
por: Hartung, Thomas
Publicado: (2021)

Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence
por: Chakraborty, Debdulal, et al.
Publicado: (2023)

Ranibizumab as an adjunct to laser for macular edema secondary to branch retinal vein occlusion
por: Azad, Rajvardhan, et al.
Publicado: (2012)

Evaluation of the Structural, Physicochemical, and Biological Characteristics of SB11, as Lucentis(®) (Ranibizumab) Biosimilar
por: Kim, Eunji, et al.
Publicado: (2022)

Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence
por: Soman, Manoj, et al.
Publicado: (2022)

Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment
por: Hatamnejad, Amin, et al.
Publicado: (2023)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

The changing landscape of biosimilars in rheumatology
por: Dörner, Thomas, et al.
Publicado: (2016)

Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes
por: Bressler, Neil M, et al.
Publicado: (2023)

The adventive flora of Tweedside
por: Hayward, Ida M.
Publicado: (1919)

The Advent of Lifestyle Medicine
por: Yeh, Byung-Il, et al.
Publicado: (2013)

The Advent of Colloidal Alkaloids
Publicado: (1917)

The Advent of Old Age
Publicado: (1873)

Second Advent of Thomsonism
Publicado: (1848)

Ranibizumab-induced retinal reperfusion and regression of neovascularization in diabetic retinopathy: An angiographic illustration
por: Chandra, Shruti, et al.
Publicado: (2018)

Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema
por: Demircan, Ali, et al.
Publicado: (2018)

Normative spectral domain optical coherence tomography data on macular and retinal nerve fiber layer thickness in Indians
por: Appukuttan, Bindu, et al.
Publicado: (2014)

An audit reviewing the management of fibroadenomas with the advent of Mammotome in the breast unit in Bradford
por: Dennis, ST, et al.
Publicado: (2008)

Treatment of age-related macular degeneration: focus on ranibizumab
por: Spitzer, Martin S, et al.
Publicado: (2008)

Diabetic papillopathy with macular edema treated with intravitreal ranibizumab
por: Kim, Moosang, et al.
Publicado: (2013)

Critical appraisal of ranibizumab in the treatment of diabetic macular edema
por: Stewart, Michael W
Publicado: (2013)

Ranibizumab plus fufang xueshuantong capsule versus ranibizumab alone for exudative age-related macular degeneration
por: Pan, Hai-Tao, et al.
Publicado: (2020)

Intravitreal Ranibizumab Versus Intravitreal Ranibizumab Combined with Posterior Subtenon Triamcinolone Acetonide in Diabetic Macular Edema
por: Karatas, Gamze, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3knsp6vh4otjtfjk92sen9etmd